Study: Similar safety, efficacy with dabigatran versus warfarin in diabetic patients with Afib
November 29th 2012Patients with nonvalvular atrial fibrillation (NVAF) who also have diabetes experienced similar safety and efficacy with dabigatran etexilate mesylate (Pradaxa) 150 mg or dabigatran 110 mg relative to warfarin, in comparison to patients without diabetes who have NVAF, according to data presented at American Heart Association's Scientific Sessions 2012.
Read More
No big surprises in ACA insurance regulations
November 26th 2012The Obama administration moved ahead to implement provisions in the healthcare law that would make it illegal for insurance companies to deny coverage for those with pre-existing conditions. Other provisions of the Affordable Care Act (ACA) also would make it easier for consumers to compare health plans and easier for employers to promote and encourage employee wellness.
Read More
Best tocolytic therapy options outlined for preterm delivery
November 21st 2012Prostaglandin inhibitors, such as celecoxib (Celebrex, Pfizer) and indomethacin (Indocin, Merck and Lundbeck) and calcium channel blockers, such as nifedipine and nicardipine (Cardene, Cornerstone Therapeutics) had the highest probability of delaying premature labor by 48 hours and improving maternal and neonatal outcomes, according to a systemic review and network meta-analysis published in a recent issue of BMJ.
Read More
Medication use for normal aging conditions overtake costs of treating most chronic diseases
November 16th 2012Prescription-drug treatment regimens for conditions are a normal part of aging are now costing the nation more than many serious and potentially life-threatening disease, according to new research from Express Scripts.
Read More
FDA Commissioner Margaret Hamburg was asked if the fungal meningitis outbreak could have been prevented by FDA during a 4-hour hearing Nov. 14 headed by the chairman of the House Energy and Commerce oversight subcommittee. Her answer was that FDA had limited authority because the New England Compounding Center (NECC), Framingham, Mass., was a ?compounding pharmacy,? which is regulated by the state Board of Pharmacy.
Read More
Sanofi lowers price of Zaltrap after Sloan-Kettering refusal to use it
November 15th 2012Sanofi is lowering the price of ziv-aflibercept (Zaltrap) for previously treated colorectal cancer by half after physicians at Memorial Sloan Kettering Cancer Center (MSKCC) said that they would not use the drug, according to The New York Times.
Read More